CHGA and adenocarcinoma: Currently, it is challenging to acquire ‘bona-fide’ CRPC-NE samples considering the rarity of these cases and also challenges in properly characterizing treatment-induced NEPC and differentiating those from adenocarcinomas based on expression of existing neuronal markers such as chromogranin A, synaptophysin and enolase 2.